MiR-134-mediated β1 integrin expression and function in mesenchymal stem cells
Research output: Contribution to journal › Research article › Contributed › peer-review
Contributors
Abstract
The composition of the hematopoietic stem cell (HSC) niche within the bone marrow is highly dynamic, tightly regulated, and of importance for various HSC properties. Integrins are important molecules within this niche that influence those properties through the interactions of HSCs and mesenchymal stem cells (MSCs). Here we investigated the function of miR-134 in integrin regulation in MSCs. In MSCs, miR-134 post-transcriptionally regulated β1 integrin expression. This negative regulation of β1 integrin was mediated by the binding of miR-134 to its 3' untranslated region, which contains two conserved binding sites for miR-134. The miR-134-mediated silencing of β1 integrin in MSCs was shown by atomic force microscopy to decrease the adhesion of 32D cells to MSCs transfected with miR-134. Furthermore, the adhesion of MSCs to fibronectin was reduced after transfection with miR-134. MSCs from patients with myelodysplastic syndrome (MDS) revealed highly significant miR-134 overexpression compared with MSCs from healthy bone marrow donors. MSCs from MDS patients showed lower β1 integrin protein, but not lower mRNA, expression, suggesting post-transcriptional regulation. The present study demonstrates miR-134-mediated negative regulation of β1 integrin that influences cell adhesion to and of MSCs. These results further contribute to our understanding of the complexity of MDS.
Details
Original language | English |
---|---|
Pages (from-to) | 3396-3404 |
Number of pages | 9 |
Journal | Biochimica et Biophysica Acta - Molecular Cell Research |
Volume | 1833 |
Issue number | 12 |
Publication status | Published - Dec 2013 |
Peer-reviewed | Yes |
External IDs
Scopus | 84886864415 |
---|---|
ORCID | /0000-0001-7803-1972/work/142235030 |
ORCID | /0000-0003-0189-3448/work/159607151 |
Keywords
ASJC Scopus subject areas
Keywords
- β1 integrin, CD29, MDS, Mesenchymal stem cells, MicroRNA, MiR-134, Myelodysplastic Syndrome, SCP-1